Could adding an antibody boost a standard CLL drug?
NCT ID NCT02007044
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial compares ibrutinib alone versus ibrutinib plus rituximab in 66 patients with relapsed chronic lymphocytic leukemia (CLL). Ibrutinib blocks cancer growth enzymes, while rituximab helps the immune system attack cancer cells. The study aims to see if the combination improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ibrutinib and rituximab
- What this could lead to
- If adding rituximab works better, this could lead to a more effective treatment option for relapsed CLL.
- What could go wrong
- This is a small, early-phase trial (66 people) and results may not apply to all patients. Adding rituximab could increase side effects without improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New transplant recipe aims to tame Graft-Versus-Host disease
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- Engineered immune cells take on tough blood cancers in early trial
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention